Genmab’s Multiple Myeloma Treatment Shines in Phase 3

An interim analysis of Genmab’s Phase 3 study for cancer candidate daratumumab yielded positive results, the company said.

Patients treated with daratumumab and a chemotherapy cocktail — lenalidomide and dexamethasone — experienced a 63 percent reduction in multiple myeloma progression versus those treated with just the other two drugs, Genmab revealed.

Further details about the trial will be presented next month at the 21st Congress of the European Hematology Association.